Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL

Stopped early · Phase 1

Conditions studied: Chronic Lymphocytic Leukemia

In brief

The purpose of the study is to evaluate the effects of increasing doses of CNF1010 on pharmacodynamic markers and hematological response.

Key facts

Study ID

NCT00319930

Run by

Biogen

People needed

10

Starts

2005-05-01

Expected to finish

2007-05-01

Last updated by the study team

2010-03-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Ocoee, Florida, United States
• Study site — Albany, New York, United States
• Study site — Dayton, Ohio, United States
• Study site — Greenville, South Carolina, United States
• Study site — Tyler, Texas, United States
• Study site — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.